ZVRA · Zevra Therapeutics, Inc. · Investor Relations
Press releases and events scraped from the company’s investor relations website. Past events open our own call or event page when we host one; otherwise listings link to the original source.
Recent news
| Date | Headline |
|---|---|
| 2026-09-02 |
Zevra Therapeutics to Present at Upcoming Investor Conferences
BOSTON, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on bringing life-changing therapeutics to people living with rare diseases, today announced that members of Zevra’s executive leadership team will present |
| 2026-08-25 |
Zevra Therapeutics to Present New Long-Term Real-World Data on MIPLYFFA® in Niemann-Pick Disease Type C (NPC) at the 2026 SSIEM Annual Symposium
Presentations from U.S. and German early access programs highlight sustained disease stabilization and a consistent safety profile across diverse NPC patient populations BOSTON, Aug. 25, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage |
| 2026-08-21 |
Zevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
BOSTON, Mass., Aug. 21, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on bringing life-changing therapeutics to people living with rare diseases, today announced that the Company has granted options to purchase an |
| 2026-08-05 |
Zevra Reports Second Quarter 2026 Financial Results and Corporate Update
$39.7 million net revenue for Q2 2026, driven by $30.2 million in revenue from MIPLYFFA 53% increase in total net revenue over Q2 2025 Operational execution fueled strong cash position of $260.2 million Company to host conference call and webcast TODAY, August 5, 2026, at 4:30 p.m. ET BOSTON, Aug. |
| 2026-08-04 |
Zevra Therapeutics to Present at the Canaccord Genuity Annual Growth Conference
BOSTON, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on bringing life-changing therapeutics to people living with rare diseases, today announced that members of Zevra’s executive leadership team will present |
| 2026-08-03 |
Zevra Therapeutics Announces Publication of Four-Year Real-World Data from U.S. Early Access Program Evaluating MIPLYFFA® (arimoclomol) in Niemann-Pick Disease Type C (NPC)
Longitudinal study includes first published real-world data on arimoclomol in adults with NPC and provides insights across a broad patient population BOSTON, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on |
| 2026-07-24 |
Zevra Therapeutics Provides Update on Regulatory Submission for Arimoclomol for the Treatment of Niemann-Pick Disease Type C (NPC) in the European Union
Company plans to request re-examination following negative CHMP opinion for arimoclomol MAA Zevra continues to support access to arimoclomol for eligible patients through its global Expanded Access Program BOSTON, July 24, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. |
| 2026-07-22 |
Zevra Therapeutics Announces Details for Q2 2026 Financial Results Call
BOSTON, Mass., July 22, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on bringing life-changing therapeutics to people living with rare diseases, today announced it will report corporate and financial results for the |
| 2026-06-23 |
Zevra Therapeutics Announces Publication of Positive MIPLYFFA® Data from Pediatric Substudy in Infants with Niemann-Pick Disease Type C (NPC)
Data published in Molecular Genetics and Metabolism Reports suggest MIPLYFFA (arimoclomol) was well tolerated in pediatric patients with no new safety signals observed BOSTON, June 23, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage |
| 2026-06-11 |
Zevra’s Chief Medical Officer to Step Down for Personal Reasons as Part of Planned Transition
BOSTON, June 11, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on bringing life-changing therapeutics to people living with rare diseases, announced today that its Chief Medical Officer (“CMO”) Adrian Quartel, M.D., |
Past events
| Date | Event | Type |
|---|---|---|
| 2026-09-15 | H.C. Wainwright 28th Annual Global Investment Conference | Conference |
| 2026-09-14 | Morgan Stanley 24th Annual Global Healthcare Conference | Conference |
| 2026-09-09 | Cantor Global Healthcare Conference | Conference |
| 2026-08-11 | CG 46th Annual Growth Conference | Conference |
| 2026-08-11 | Canaccord Genuity 46th Annual Growth Conference | Conference |
| 2026-08-05 | Zevra Therapeutics Q2 2026 Earnings Call | Earnings call |
| 2026-05-19 | H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ | Conference |
| 2026-05-06 | Zevra Therapeutics Q1 2026 Earnings Call | Earnings call |
| 2026-03-11 | Citizens Life Sciences Conference | Conference |
| 2026-03-09 | Zevra Therapeutics Q4 and Full Year 2025 Earnings Call | Earnings call |
| 2025-11-05 | Zevra Therapeutics Q3 2025 Earnings Call | Earnings call |
| 2025-08-12 | Zevra Therapeutics Q2 2025 Earnings Call | Earnings call |
| 2025-05-13 | Zevra Therapeutics Q1 2025 Earnings Call | Earnings call |
| 2025-03-11 | Zevra Therapeutics Fourth Quarter and Full Year 2024 Results | Event |
Source: https://investors.zevra.com/